# Page 108 Audit — Biographic & Disclosure: Caramori (cont), Chan, Heerspink (7 Spans)

## Page Identity
- **PDF page**: S107 (Biographic and Disclosure Information — www.kidney-international.org)
- **Content**: Caramori bio conclusion + COI; Juliana C.N. Chan full bio + COI (HKDR, JADE Technology, Lancet Commission); Hiddo J.L. Heerspink bio (start) — all with disclosure statements
- **Clinical tier**: T3 (Informational — author biographies and disclosures)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: YES (shown in UI, though only F channel present — may be internal F sub-model disagreement)

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 7 |
| T1 (Patient Safety) | 0 |
| T2 (Clinical Accuracy) | 7 |
| T3 (Informational) | 0 |
| Channels present | F (NuExtract LLM) |
| Pre-reviewed spans | 1 (REJECTED) |
| Tier accuracy | 0% (0/7) |
| Disagreements | 1 |
| Review Status | PENDING: 6, REJECTED: 1 |
| Cross-Check | 2026-02-25 — counts verified against raw extraction data |
| Audit Date | 2026-02-25 (revised) |

## All Spans

| # | Text | Channel | Conf | Tier | Status | Correct Tier | Issue |
|---|------|---------|------|------|--------|-------------|-------|
| 1 | "consultancy fees from AstraZeneca*, Bayer Pharmaceuticals*, Boehringer Ingelheim*, Celltrion, Merck Sharp & Dohme*, Nova..." | F | 85% | T2 | **REJECTED** | T3 | Chan COI — consultancy list |
| 2 | "grant support from Applied Therapeutics*, AstraZeneca*, Eli Lilly and Company*, Hua Medicine*, Lee Powder*, Merck*, Pfiz..." | F | 85% | T2 | PENDING | T3 | Chan COI — grants list |
| 3 | "speaker fees from AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim*, Merck*, Merck Sharp & Dohme*, Sanofi*, Viat..." | F | 85% | T2 | PENDING | T3 | Chan COI — speaker fees |
| 4 | "educational presentations for Boehringer Ingelheim*;" | F | 85% | T2 | PENDING | T3 | Chan COI — education |
| 5 | "being founding director and shareholder of startup biogenetic testing company GEMVCARE, with partial support by the Hong..." | F | 85% | T2 | PENDING | T3 | Chan COI — business interests |
| 6 | "being co-inventor for the patent of biomarkers for predicting diabetes and its complications." | F | 85% | T2 | PENDING | T3 | Chan COI — patents |
| 7 | "*Monies paid to institution." | F | 90% | T2 | PENDING | T3 | Disclosure footnote (also on p107) |

### Notable: Pre-Existing REJECTED Span
Span 1 has already been reviewed and REJECTED by a prior reviewer. This is the first REJECTED span observed in the biographic section. The rejection is appropriate — COI disclosures are not clinical content.

### F Channel Fragmentation Pattern (Continued)
Same pattern as page 107: F channel splits Chan's COI disclosure into 6 separate spans (1-6), one per disclosure category (consultancy → grants → speaker → education → business → patents). The LLM treats each semicolon-delimited clause as a separate extractable entity.

### No HTML Artifact
Notably, no `<!-- PAGE 108 -->` HTML artifact on this page — the first biographic page without one. The HTML artifact pattern is inconsistent (present on ~11 of 18 post-page-98 pages).

## PDF Source Content
- **M. Luiza Caramori** (continued): NIH R01 grant for protective factors in DKD; KDOQI Work Group member; ADA Scientific Sessions diabetic nephropathy subcommittee past-chair
- **Caramori COI**: AstraZeneca, Bayer, Boehringer Ingelheim (consultancy); Bayer*, Boehringer Ingelheim*, Novartis (grants); Bayer (speaker)
- **Juliana C.N. Chan, MBChB, MD**: Chair professor at Chinese University of Hong Kong; HKDR 1995; JADE Technology 2007; 500+ publications; ADA Harold Rifkin Award 2019; Lancet Commission on Diabetes 2020
- **Chan COI**: AstraZeneca*, Bayer*, Boehringer Ingelheim*, Celltrion, MSD*, Novartis*, Roche*, Sanofi*, Viatris* (consultancy); Applied Therapeutics*, AstraZeneca*, Eli Lilly*, Hua Medicine*, Lee Powder*, Merck*, Pfizer*, Servier* (grants); AstraZeneca, Bayer, Boehringer Ingelheim*, Merck*, MSD*, Sanofi*, Viatris* (speaker); Boehringer Ingelheim* (education); GEMVCARE (business); biomarker patent (IP)
- **Hiddo J.L. Heerspink, PhD, PharmD**: Professor at University Medical Center Groningen; visiting professor UNSW Sydney; clinical trialist focused on kidney/CV complications in T2D; personalized medicine; 350+ publications; Harry Keen Award from EASD
- **Heerspink COI** (starts, continues on next page): Abbvie*, AstraZeneca*, Bayer*, Boehringer Ingelheim*, Chinook*, CSL Behring*, Dimerix, Gilead*, Goldfinch Bio, Janssen*, Merck*, Mitsubishi Tanabe*, Mundipharma...

## Quality Assessment
| Dimension | Rating | Notes |
|-----------|--------|-------|
| Tier accuracy | 0% | All should be T3 — author biographies and disclosures |
| Clinical safety risk | NONE | Biographical information and COI statements |
| Key pattern | F channel fragments COI by disclosure category |
| Pipeline bugs | 0 | No HTML artifact on this page |

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. Author biographies and conflict-of-interest disclosures.

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Page in sequence**: 108 of 126
